Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  CanSino Biologics Inc.    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
End-of-day quote. End-of-day quote Hong Kong Stock Exchange - 08/10
222.2 HKD   -7.80%
08/09CanSino to start Phase III trial of COVID-19 vaccine in Saudi
RE
08/07AstraZeneca Sets Deal in China Market -- WSJ
DJ
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
08/04/2020 08/05/2020 08/06/2020 08/07/2020 08/10/2020 Date
258.4 254.8 251.6 241 222.2 Last
1707189 1071830 1153588 1228386 2057484 Volume
-0.69% -1.39% -1.26% -4.21% -7.80% Change
Financials
Sales 2020 122 M 17,5 M 17,5 M
Net income 2020 -109 M -15,7 M -15,7 M
Net Debt 2020 31,6 M 4,55 M 4,55 M
P/E ratio 2020 -359x
Yield 2020 -
Sales 2021 835 M 120 M 120 M
Net income 2021 183 M 26,2 M 26,2 M
Net cash position 2021 1 194 M 172 M 172 M
P/E ratio 2021 296x
Yield 2021 -
Capitalization 49 473 M 6 383 M 7 110 M
EV / Sales 2020 406x
EV / Sales 2021 57,8x
Nbr of Employees 429
Free-Float 44,0%
More Financials
Company
CANSINO BIOLOGICS INC., formerly Tianjin CanSino Biotechnology Inc., is a China-based company principally engaged in the research and development, manufacture and commercialization of vaccine products for human use. The Company’s core products consist of two vaccine candidates, namely MCV4 candidate and MCV2 candidate. The Company mainly operates its business in the domestic market. 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of CanSino Biologics Inc.
Trading Rating : Investor Rating : -
More Ratings
Latest news on CANSINO BIOLOGICS INC.
08/09CanSino to start Phase III trial of COVID-19 vaccine in Saudi
RE
08/07AstraZeneca Sets Deal in China Market -- WSJ
DJ
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
08/05Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccines
RE
07/30A BIG OBSTACLE : Where can CanSino test its vaccine abroad?
RE
07/30A BIG OBSTACLE : Where can CanSino test its vaccine abroad?
RE
07/29CANSINO BIOLOGICS : Inside information determination of the offer size and issue..
PU
07/26CANSINO BIOLOGICS : Inside information cooperation with pfizer to promote mcv4 p..
PU
07/24WHO scientist sees regulators cooperating to speed COVID-19 vaccine approval
RE
07/23China's Sinopharm says coronavirus vaccine could be ready by year-end - state..
RE
07/23China's Sinopharm says coronavirus vaccine could be ready by year-end - state..
RE
07/22CANSINO BIOLOGICS : Inside information preliminary price consultation period of ..
PU
07/21EU recovery fund lifts shares to five-month high
RE
07/21EU recovery fund sends shares, euro to 4-month highs
RE
07/21Three Leading Vaccine Candidates Show Promise in Fresh Trial Data -- WSJ
DJ
More news
News in other languages on CANSINO BIOLOGICS INC.
08/09CanSino to start Phase III trial of COVID-19 vaccine in Saudi
08/07AstraZeneca Sets Deal in China Market -- WSJ
08/06AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
08/05Canada signs deals with Pfizer, Moderna for experimental COVID-19 vaccines
07/30A BIG OBSTACLE : Where can CanSino test its vaccine abroad?
More news
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 156,25 CNY
Last Close Price 222,20 CNY
Spread / Highest target 6,72%
Spread / Average Target -29,7%
Spread / Lowest Target -78,0%
EPS Revisions
Managers
NameTitle
Xue Feng Yu Chairman, Chief Executive Officer & GM
Jiang Feng Li Chairman-Supervisory Board
Shou Bai Chao COO, Executive Director & Deputy General Manager
Jing Wang Chief Financial Officer & Board Secretary
Tao Zhu Executive Director, CSO & Deputy General Manager
Sector and Competitors
1st jan.Capitalization (M$)
CANSINO BIOLOGICS INC.276.93%6 923
CSL LIMITED1.36%89 334
BIOGEN INC.3.03%48 398
SAMSUNG BIOLOGICS CO.,LTD.78.06%42 742
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.222.55%36 982
WUXI BIOLOGICS (CAYMAN) INC.68.68%29 772